Biologics Provide Lasting Care for Degenerative Disc Disease

3:30 minute video

Dr. Roger Hӓrtl, neurosurgical director of Och Spine at NewYork-Presbyterian and Weill Cornell Medicine, discusses novel biological solutions for degenerative disc disease that aim to address disc reherniation, revision procedures for corrective surgery, and other common yet persistent issues in spine care. Biologics for disc regeneration, repair, and replacement have the potential to provide patients with a one-time treatment across every stage of degenerative disc disease. These minimally invasive approaches are being developed to enhance outcomes and improve quality of life for patients.

Episode Transcript

Roger Härtl, MD
Roger Härtl, MD

Neurological Surgery